Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: A controlled-real life study

被引：8
作者：
Djuric-Filipovic I. [1 ]
Caminati M. [2 ]
Filipovic D. [3 ]
Salvottini C. [4 ]
Zivkovic Z. [5 ,6 ]
机构：
[1] University of Kragujevac, Faculty of Medical Science, Svetozara Markovica 64, Kragujevac
[2] Verona University and General Hospital, Allergy Unit and Asthma Center, Piazzale Stefani 1, Verona
[3] Institution for Emergency Medical Care, Bulevar Franša Depera 5, Belgrade
[4] University of Pavia, Department of Internal Medicine and Therapeutics, Strada Nuova 65, Pavia
[5] Medical Center Dr. Dragiša Mišović, Children's Hospital for Lung Diseases and Tuberculosis, Belgrade, Pilota Mihajla Tepica 1, Belgrade
[6] University Business Academy in Novi Sad, Faculty of Pharmacy, Trg Mladenca 5, 2100, Novi Sad
来源：
Clinical and Molecular Allergy | / 15卷 / 1期
关键词：
Allergen specific immunotherapy; Asthma; Childhood; Exhaled NO;
D O I：
10.1186/s12948-017-0064-5
中图分类号：
学科分类号：
摘要：
Background: Allergen-specific immunotherapy (AIT) is the only treatment able to change the natural course of allergic diseases. We aimed at investigating the clinical efficacy of SLITOR (Serbian registered vaccine for sublingual allergen specific immunotherapy). Methods: 7-18 years old children with allergic asthma and rhinitis were enrolled and addressed to the active (AIT plus pharmacological treatment) or control (standard pharmacological treatment only) group. Clinical and medications scores, lung function and exhaled FeNO were measured at baseline and at every follow-up. Results: There was a significant improvement in both nasal and asthma symptom scores as well as in medication score in SLIT group. SLIT showed an important influence on lung function and airway inflammation. Conclusions: Our data showed that SLITOR was effective not only in terms of patient reported outcomes but an improvement of pulmonary function and decrease of lower airway inflammation were also observed. © 2017 The Author(s).
引用
收藏
相关论文
共 41 条
[1]  
Gough H., Grabenhenrich L., Reich A., Et al., Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS, Pediatr Allergy Immunol, 26, pp. 431-437, (2015)
[2]  
Caminati M., Duric-Filipovic I., Arasi S., Peroni D.G., Zivkovic Z., Senna G., Respiratory allergies in childhood: recent advances and future challenges, Pediatr Allergy Immunol, 26, pp. 702-710, (2015)
[3]  
Alduraywish S.A., Lodge C.J., Campbell B., Et al., The march from early life food sensitization to allergic disease: a systematic review and meta-analyses of birth cohort studies, Allergy, (2015)
[4]  
Arasi S., Passalacqua G., Caminiti L., Crisafulli G., Fiamingo C., Pajno G.B., Efficacy and safety of sublingual immunotherapy in children, Expert Rev Clin Immunol., 12, 1, pp. 49-56, (2016)
[5]  
Zivkovic Z., Cerovic S., Djuric-Filipovic I., Vukasinovic Z., Jocic-Stojanovic J., Bajec-Opancina A., Clinical implications and facts about allergic rhinitis (AR) in children, allergic
[6]  
Caminati M., Dama A.R., Djuric I., Montagni M., Schiappoli M., Ridolo E., Senna G., Canonica G.W., Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety, Expert Rev Clin Immunol., 11, 2, pp. 233-245, (2015)
[7]  
Duric-Filipovic I., Caminati M., Kostic G., Filipovic, Zivkovic Z., Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis, World J Pediatr., 12, 3, pp. 283-290, (2016)
[8]  
Zivkovic Z., Djuric-Filipovic I., Zivanovic S., Current issues on sublingual allergen-specific immunotherapy in children with asthma and allergic rhinitis, Srp Arh Celok Lek, 144, 5-6, pp. 345-350, (2016)
[9]  
Passalacqua G., Canonica G.W., Allergen immunotherapy: history and future developments, Immunol Allergy Clin North Am., 36, 1, pp. 1-12, (2016)
[10]  
Jutel M., Agache I., Bonini S., Burks A.W., Calderon M., Canonica W., Et al., International consensus on allergy immunotherapy, J Allergy Clin Immunol., 136, 3, pp. 556-568, (2015)
12345